Compare BHR & LUCD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BHR | LUCD |
|---|---|---|
| Founded | 2013 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 159.3M | 190.8M |
| IPO Year | N/A | 2021 |
| Metric | BHR | LUCD |
|---|---|---|
| Price | $2.38 | $1.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $4.13 |
| AVG Volume (30 Days) | 340.4K | ★ 772.2K |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | ★ 8.44% | N/A |
| EPS Growth | N/A | ★ 16.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,346,000.00 |
| Revenue This Year | N/A | $115.58 |
| Revenue Next Year | N/A | $130.54 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 79.00 |
| 52 Week Low | $1.85 | $0.95 |
| 52 Week High | $3.19 | $1.70 |
| Indicator | BHR | LUCD |
|---|---|---|
| Relative Strength Index (RSI) | 42.49 | 38.07 |
| Support Level | $2.34 | $1.02 |
| Resistance Level | $2.62 | $1.14 |
| Average True Range (ATR) | 0.10 | 0.08 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 27.14 | 4.01 |
Braemar Hotels & Resorts Inc is a real estate investment trust company that invests in high revenue per available room, or RevPAR, luxury hotels and resorts. The firm operates in various U.S. states such as California, Texas, Washington, Philadelphia, Florida, and Illinois as well as Washington, D.C. and St. Thomas, U.S. Virgin Islands. The company operates through its direct hotel investment segment of the hotel lodging industry. Its revenue streams include rooms, food and beverage, and other. The firm's hotels operate under various brands, such as Marriott, Hilton, Courtyard, and, among others.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.